ResearcherNational Hospital OrganizationActive in the last 2 years
Yosuke Shimizu
Matched on OpenAlex author ID A5121002583. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2026: 3 papers
Papers 3
- Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential tyrosine receptor kinase inhibitors. Last author DOI 10.1007/s12328-026-02388-z↗
- TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20228-9↗
- ASO Visual Abstract: TMPRSS4 Expression Predicts Survival and Benefit From Neoadjuvant Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-20329-5↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Takeshi Sudo · 3 shared papers, 2026 · strength 0.79
- Paper Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential… DOI 10.1007/s12328-026-02388-z↗
- Paper TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer. DOI 10.1245/s10434-026-20228-9↗
- Paper ASO Visual Abstract: TMPRSS4 Expression Predicts Survival and Benefit From Neoadjuvant Chemotherapy in Pancreatic Cance… DOI 10.1245/s10434-026-20329-5↗
- Shinya Takahashi · 3 shared papers, 2026 · strength 0.79
- Paper Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential… DOI 10.1007/s12328-026-02388-z↗
- Paper TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer. DOI 10.1245/s10434-026-20228-9↗
- Paper ASO Visual Abstract: TMPRSS4 Expression Predicts Survival and Benefit From Neoadjuvant Chemotherapy in Pancreatic Cance… DOI 10.1245/s10434-026-20329-5↗
- Hirotaka Tashiro · 3 shared papers, 2026 · strength 0.79
- Paper Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential… DOI 10.1007/s12328-026-02388-z↗
- Paper TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer. DOI 10.1245/s10434-026-20228-9↗
- Paper ASO Visual Abstract: TMPRSS4 Expression Predicts Survival and Benefit From Neoadjuvant Chemotherapy in Pancreatic Cance… DOI 10.1245/s10434-026-20329-5↗
- Kenta Baba · 3 shared papers, 2026 · strength 0.79
- Paper Long-term disease control of GP2-NTRK1 fusion-positive pancreatic adenocarcinoma with liver metastases using sequential… DOI 10.1007/s12328-026-02388-z↗
- Paper TMPRSS4 Expression Predicts Survival and Benefit from Neoadjuvant Chemotherapy in Pancreatic Cancer. DOI 10.1245/s10434-026-20228-9↗
- Paper ASO Visual Abstract: TMPRSS4 Expression Predicts Survival and Benefit From Neoadjuvant Chemotherapy in Pancreatic Cance… DOI 10.1245/s10434-026-20329-5↗
- Tatsuaki Sumiyoshi · 1 shared paper, 2026 · strength 0.29
- Sho Tazuma · 1 shared paper, 2026 · strength 0.29
- Kenichiro Uemura · 1 shared paper, 2026 · strength 0.29
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.